- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03936478
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)
A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin Carbone Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
For all participants
- Participants should have no contraindications to undergo MRI scan as part of radiotherapy planning and treatment.
- Lumpectomy cavity must be clearly visible on CT and MRI scan at radiotherapy simulation.
- Pregnancy test negative in women of child bearing potential (WOCBP).
- The participant must consent to be in the study and must have signed an approved consent form conforming with institutional guidelines.
- Participants with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior and are deemed by their physician to be at low risk for recurrence. Participants with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
For participants with Invasive Carcinoma
Suitable:
Age: >=50 years
- Margins: Negative by at least 2 mm
- T Stage: Tis or T1
Cautionary:
Age: 40-49 years
- Margins: Negative by at least 2 mm
- T Stage: Tis or T1 OR
Age: >=50 years IF participant has at least 1 of the pathologic factors below and does not have any "unsuitable" factors (below)
Pathologic Factors:
- Size 2.1-3.0 cm (size of the invasive component)
- T2
- Close margins (<2 mm)
- Limited/focal Lymphovascular Space Invasion (LVSI)
- ER (-)
- Clinically unifocal with total size 2.1-3.0 cm (Microscopic multifocality allowed, provided the lesion is clinically unifocal (a single discrete lesion by physical examination and ultrasonography/mammography) and the total lesion size (including foci of multifocality and intervening normal breast parenchyma) falls between 2.1 and 3.0 cm).
- Invasive lobular histology
- Extensive Intraductal Component (EIC) <=3 cm
For participants with DCIS
Suitable Criteria, DCIS allowed if all of the following are met:
- Screen-detected
- Low to intermediate nuclear grade
- Size <=2.5 cm
- Resected with margins negative at >=3mm OR
Cautionary Criteria:
- Pure DCIS <=3 cm if "suitable" criteria not fully met
Exclusion Criteria (unsuitable criteria) :
- Men are not eligible for this study.
- BRCA1/2 mutation positivity.
- Age < 40 years (American Society for Radiation Oncology (ASTRO) Unsuitable Criteria).
- Positive resection margins on post operative pathology(ASTRO Unsuitable Criteria).
- Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
- Suspicious micro calcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
- Non-epithelial breast malignancies such as sarcoma or lymphoma.
- Proven multicentric carcinoma (invasive cancer or DCIS) (ASTRO Unsuitable Criteria).
- Pure DCIS >3 cm in size (ASTRO Unsuitable Criteria).
- Presence of extensive intraductal component >30mm (ASTRO Unsuitable Criteria).
- Paget's disease of the nipple.
- History of previous invasive breast cancer, DCIS, synchronous bilateral invasive or non-invasive breast cancer. (Participants with a history of LCIS treated by surgery alone are eligible.)
- Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation.
- Concurrent therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, Aromatase Inhibitors or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention or neoadjuvant therapy.
- Breast implants.
- Prior breast or thoracic radiotherapy for any condition or treatment plan that includes regional nodal irradiation.
- Collagen vascular disease, specifically dermatomyositis with a creatinine phosphokinase level above normal or with an active skin rash, systemic lupus erythematosus, or scleroderma.
- Pregnancy or lactation at the time of treatment. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the participant from meeting the study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 8.2 Gy Radiation Therapy
Accelerated partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm PTV margin.
Treatment duration will be 5-6 days and treatments will be on alternative weekdays, with a minimum interval of 40 hours between subsequent fractions.
|
partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physician Reported Cosmesis: 1-year
Time Frame: up to 1-year
|
The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment.
The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor).
The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis.
Scoring is objective with lower scores indicating improved conditions.
|
up to 1-year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Quality of Life: BCTOS Survey
Time Frame: up to 5 years
|
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Breast Cancer Treatment Outcomes Scale (BCTOS) is a 22-item scale scored 1-4 where 1 is none, 2 is slight, 3 is moderate, and 4 is large.
Total score ranges from 22-88 where lower scores indicated better outcomes.
|
up to 5 years
|
Participant Quality of Life: Convenience of Care Scale
Time Frame: up to 5 years
|
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.
The Convenience of Care scale is an 8-item scale scored 0 (not at all) to 10 (a lot).
The total score ranges from 0-80 where lower scores indicate less disruptive interventions.
|
up to 5 years
|
Participant Quality of Life: MOS SF-36 Survey
Time Frame: up to 5 years
|
Participant Quality of Life will be assessed prior to starting treatment, at end of radiotherapy (RT), 4 weeks post RT, 6 months post RT, 12 months post RT and yearly through 5 years by collecting measures from three scales.The Medical Outcomes Study Short Form - 36 (MOS SF-36) Vitality scale measures how a participant has felt in the last 4 weeks.
4-items are scored from 1-5 where 1 is all of the time and 5 is none of the time.
4-items are scored from 0 (no pain) to 10 (pain as bad as you can imagine).
Total score ranges from 4-60 where lower scores indicate increased vitality.
|
up to 5 years
|
Physician Reported Cosmesis: 3-year
Time Frame: up to 3 years
|
The Harvard Cosmesis Scale will be used to report cosmesis at 1 year post treatment.
The physician will report how the breast looks relative to original appearance or untreated breast (excellent, good, fair, poor).
The physician answers 9 questions on a scale of 0-2 where 0 is none, 1 is present but does not affect cosmesis, 2 is present and affects cosmesis.
Scoring is objective with lower scores indicating improved conditions.
|
up to 3 years
|
Physician Evaluated Fat Necrosis
Time Frame: up to 5 years
|
Fat necrosis will be assessed prior to treatment, at 6 months post RT, at 12 months post RT, and yearly through 5 years, graded as follows: Grade 0 is no fat necrosis, Grade 1 is Asymptomatic fat necrosis (only radiologic and/or cytologic findings), Grade 2 is Symptomatic fat necrosis not requiring medication (palpable mass with or without mild pain), Grade 3 is Symptomatic fat necrosis requiring medication (palpable mass with significant pain), Grade 4 is Symptomatic fat necrosis requiring surgical intervention.
|
up to 5 years
|
Acute Radiation Toxicity
Time Frame: up to 90 days from completion of radiation therapy
|
The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of acute toxicities.
Acute toxicities will be scored from the start of radiation to 90 days after completion of radiotherapy and late toxicities will be scored > 90 days from completion of radiation therapy.
|
up to 90 days from completion of radiation therapy
|
Late Radiation Toxicity
Time Frame: up to 5 years
|
The NCI's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used to identify the type and to grade the severity of late toxicities.
|
up to 5 years
|
Ipsilateral Breast Tumor Recurrence (IBTR)
Time Frame: up to 5 years
|
Defined as evidence of invasive or in situ breast cancer (except LCIS) in the ipsilateral breast.
Participants who develop clinical evidence of tumor recurrence in the remainder of the ipsilateral breast must have a biopsy of the suspicious lesion to confirm the diagnosis with documentation of the location.
|
up to 5 years
|
Ipsilateral Regional Nodal Recurrence
Time Frame: up to 5 years
|
Defined as the development of tumor in the ipsilateral internal mammary, ipsilateral supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes, as well as the soft tissue of the ipsilateral axilla, after operation.
|
up to 5 years
|
Disease Free Survival (DFS)
Time Frame: up to 5 years
|
Disease free survival (DFS) defined as the time from start of radiation to the time of documented recurrent disease in the ipsilateral breast or regional nodes (supraclavicular, axillary or internal mammary) or distant sites (e.g.
bone, liver, lung or brain).
|
up to 5 years
|
Overall Survival (OS)
Time Frame: up to 5 years
|
Overall survival (OS) defined as the time from start of radiation to death from any cause.
|
up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bethany Anderson, MD, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW18099
- A533300 (Other Identifier: UW Madison)
- 2019-0322 (Other Identifier: Institutional Review Board)
- SMPH\HUMAN ONCO\HUMAN ONCO (Other Identifier: UW Madison)
- NCI-2019-03111 (Registry Identifier: NCI Trial ID)
- Protocol Version 5/10/2021 (Other Identifier: UW Madison)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on MRIdian Radiation Treatment Unit
-
Indiana UniversityState University of New York at Buffalo; Tufts University School of Dental...CompletedDental CariesUnited States
-
University Hospital of CologneAlbert Einstein College of Medicine; Monash University; The Alfred; Johann Wolfgang... and other collaboratorsNot yet recruiting
-
Koç UniversityTerminatedCovid19 | Sarcopenia | Intensive Care Unit Acquired WeaknessTurkey
-
University of MontanaNational Institute of Environmental Health Sciences (NIEHS)CompletedRespiratory Infection Other | Respiratory; Disorder, Functional, ImpairedUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Ontario Clinical Oncology Group (OCOG)RecruitingBreast Neoplasms | Lymphedema | RadiotherapyCanada
-
The University of Texas Health Science Center at...CompletedHead and Neck NeoplasmsUnited States
-
Summa Health SystemTerminatedAdvanced Bulky MalignanciesUnited States
-
William Beaumont HospitalsRecruitingMultiple Sclerosis | Overactive BladderUnited States
-
AHS Cancer Control AlbertaUnknownHigh-risk Prostate CancerCanada